KHO Pil Su (KR),ХО Пил Су (KR),JOON Dong Okh (KR),ЙООН Донг Ох (KR),KHAN Sun Joung (KR),ХАН Сун Йоунг (KR),LI Von Il (KR),ЛИ Вон Ил (KR),KIM Dzung Sook (KR),КИМ Дзунг Соок (KR),PARK Voul Seong (KR),ПА,KHO Pil Su,ХО Пил Су,JOON Dong Okh,ЙООН Донг Ох,KHAN Sun Joung,ХАН Сун Йоунг,LI Von Il,ЛИ Вон Ил,KIM Dzung Sook,КИМ Дзунг Соок,PARK Voul Seong,ПАРК Воул Сеонг,AKHN Sung Okh,АХН Сунг Ох,KIM Khie Dzung
申请号：
RU2014115478
公开号：
RU0002628074C2
申请日:
2012.09.28
申请国别(地区):
RU
年份:
2017
代理人:
摘要：
FIELD: pharmacology.SUBSTANCE: invention relates to a heterocyclic compound of formula 1,or to a racemate, isomer, or pharmaceutically acceptable salt thereof, wherein X1 and X2 are C； each of X3 and X4 is independently C or N, provided that one of X3 and X4 is N； R1 is a saturated 4-9 member mono- or bi-heterocyclyl containing 1-2 heteroatoms (where the heteroatoms are N), where R1 is unsubstituted or substituted by 1 to 3 substituents selected from -NR6R7 and R8； or R1 is selected from -NR6R7 and R8； R2, R3, R4 and R5 may be the same or different； and each is independently selected from -H； -C1-C6alkyl； -C1-C6haloalkyl； -C1 -C6perhaloalkyl； -halogen (-F, -Cl, -Br, -I)； -CN； -C1-C6talkoxy； -C1-C6haloalkoxy； -C1-C6perhaloalkoxy； C2alkenyl； -C2-C3alkynyl； -amino； -OH； -nitro (-NO2)； -C6-C1aryl； and furan； provided that, when X3 is N, R4 is absent； and when X4 is N, R5 is absent, each of Y1, Y2, Y3, Y4 and Y5 is independently C or a heteroatom (preferably a heteroatom independently selected from N, O and S), provided that at least two of Y1, Y2, Y3, Y4 and Y5 are heteroatoms independently selected from N and O； each of Y2 and Y3 can be independently substituted by R9； Y4 may be substituted with -H or -C1-C6alkyl； each of R6 and R7 is independently selected from -H； -C1-C6alkyl； and -carboxyl (-COOH)； R8 is -C1-C6alkyl or -C3cycloalkyl； and R9 is selected from -H； -C1-C6alkyl； and -C3cycloalkyl； wherein the alkyl and heterocyclyl may be independently unsubstituted or substituted by one or more substituents (for example, 1 to 3 substituents) selected from the group consisting of -C1-C4alkyl, -C1-C4alkoxy and -OH. The invention also relates to particular compounds and a pharmaceutical composition based on the said compounds.EFFECT: new heterocyclic compounds useful for human histamine receptor 4 inhibition are obtained.13 cl, 13 tbl, 144 exИзобретение относится к области органической химии, а именно к гетероциклическому соединению формулы 1, или к его рацемату, изомеру,
